In a real-world study, cytoreductive nephrectomy (CN) prior to treatment with tyrosine kinase inhibitors did not improve survival for CN recipients overall, but did improve cancer-specific and progression-free survival in certain subgroups.
Lenvatinib plus pembrolizumab resulted in antitumor activity in patients with metastatic clear cell RCC that progressed during or after treatment with an immune checkpoint inhibitor, according to phase 2 results.
The response-based addition of ipilimumab to nivolumab in the treatment of advanced RCC resulted in few responses among patients who did not achieve a response with nivolumab alone, according to results of a phase 2 trial.
Preliminary phase 2 data suggest that nivolumab plus ipilimumab was efficacious in advanced RCC that previously progressed with immune checkpoint inhibitor therapy.
A HIF-2α inhibitor demonstrated antitumor activity against VHL-associated clear cell RCC and other associated tumors, according to interim results of a phase 2 study.
The phase 3 PROSPER RCC trial will evaluate neoadjuvant with adjuvant nivolumab among patients with nonmetastatic RCC compared with surgery and standard-of-care surveillance.
In a study involving stage 3 RCC patients, those with positive lymph nodes had markedly inferior 5-year survival compared with those with lymph-node negative disease and 5-year survival similar to those with stage 4 RCC.
10-year disease-specific survival 94%; 10-year risk for hemodialysis only 2.3%.
Lung metastases are most common in clear cell renal cell carcinoma, whereas lymph node metastases and liver metastases occur most frequently in papillary and chromophobe RCC, respectively, investigators reported.
Previous findings from the TIVO-3 trial showed that tivozanib offered superior progression-free survival compared with sorafenib in patients with refractory metastatic renal cell carcinoma, but the latest analysis found no significant difference in overall survival.
